These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14563529)

  • 21. Genotoxicity of several clinically used topoisomerase II inhibitors.
    Boos G; Stopper H
    Toxicol Lett; 2000 Jul; 116(1-2):7-16. PubMed ID: 10906417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.
    Pérez C; Vilaboa NE; García-Bermejo L; de Blas E; Creighton AM; Aller P
    J Cell Sci; 1997 Feb; 110 ( Pt 3)():337-43. PubMed ID: 9057086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High yield of endoreduplication induced by ICRF-193: a topoisomerase II catalytic inhibitor.
    Pastor N; José Flores M; Domínguez I; Mateos S; Cortés F
    Mutat Res; 2002 Apr; 516(1-2):113-20. PubMed ID: 11943617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
    Muñoz P; Baus F; Piette J
    Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin.
    Orta ML; Mateos S; Cortés F
    Mutagenesis; 2009 May; 24(3):237-44. PubMed ID: 19201781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of the DNA topoisomerase II catalytic inhibitor meso-2,3-bis(3,5-dioxopiperazine-1-yl)butane (ICRF-193), a bisdioxopiperazine derivative, with the conserved region(s) of eukaryotic but not prokaryotic enzyme.
    Sato M; Ishida R; Narita T; Kato J; Ikeda H; Fukazawa H; Andoh T
    Biochem Pharmacol; 1997 Sep; 54(5):545-50. PubMed ID: 9337070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
    Beere HM; Chresta CM; Hickman JA
    Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication.
    Pastor N; Domínguez I; Orta ML; Campanella C; Mateos S; Cortés F
    Mutat Res; 2012; 738-739():45-51. PubMed ID: 22921906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1).
    Isik S; Sano K; Tsutsui K; Seki M; Enomoto T; Saitoh H; Tsutsui K
    FEBS Lett; 2003 Jul; 546(2-3):374-8. PubMed ID: 12832072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ICRF-193 modifies etoposide-induced apoptosis in thymocytes.
    Tanimoto C; Hirakawa S; Kawasaki H; Hayakawa N; Ota Z
    Acta Med Okayama; 1995 Dec; 49(6):281-6. PubMed ID: 8770236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P; Beardmore C; Liu LF
    Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catalytic inhibitors of DNA topoisomerase II.
    Andoh T; Ishida R
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):155-71. PubMed ID: 9748552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
    Onishi Y; Azuma Y; Kizaki H
    Biochem Mol Biol Int; 1994 Jan; 32(1):115-22. PubMed ID: 8012276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of radiation response by inhibiting topoisomerase II catalytic activity.
    Mateos S; Hajji N; Pastor N; Cortés F
    Mutat Res; 2006 Jul; 599(1-2):105-15. PubMed ID: 16574164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA damage and topoisomerase II inhibition induced by a benzopsoralen derivative.
    Pani B; Barbisin M; Russo E; Tamaro M; Baccichetti F; Carlassare F; Marzano C; Rodighiero P; Bordin F
    Mutat Res; 1994 Dec; 311(2):277-85. PubMed ID: 7526193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs.
    Andoh T
    Biochimie; 1998 Mar; 80(3):235-46. PubMed ID: 9615863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.
    Ishida R; Sato M; Narita T; Utsumi KR; Nishimoto T; Morita T; Nagata H; Andoh T
    J Cell Biol; 1994 Sep; 126(6):1341-51. PubMed ID: 8089169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
    Hasinoff BB; Kuschak TI; Yalowich JC; Creighton AM
    Biochem Pharmacol; 1995 Sep; 50(7):953-8. PubMed ID: 7575679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotoxic effects of the alkaloids harman and harmine assessed by comet assay and chromosome aberration test in mammalian cells in vitro.
    Boeira JM; da Silva J; Erdtmann B; Henriques JA
    Pharmacol Toxicol; 2001 Dec; 89(6):287-94. PubMed ID: 11903953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
    Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
    Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.